6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
2	NCT02424708 (ClinicalTrials.gov)	April 2015	15/4/2015	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo	Bastyr University	Michael J. Fox Foundation for Parkinson's Research	Completed	21 Years	N/A	Both	45	Phase 2	United States
3	NCT02324426 (ClinicalTrials.gov)	December 2014	4/12/2014	CNS Uptake of Intranasal Glutathione	Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione	University of Washington	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	Both	15	Phase 1	United States
4	NCT01398748 (ClinicalTrials.gov)	July 2012	19/7/2011	Intranasal Glutathione in Parkinson's Disease	A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease	Parkinson's Disease (PD)	Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery	Bastyr University	National Center for Complementary and Integrative Health (NCCIH)	Completed	21 Years	100 Years	All	34	Phase 1	United States
5	NCT01177319 (ClinicalTrials.gov)	September 2003	5/8/2010	Glutathione (GSH) In The Treatment of Parkinson's Disease	Glutathione (GSH) In The Treatment of Parkinson's Disease	Parkinson's Disease	Drug: Glutathione	University of South Florida	Wellness Health & Pharmaceuticals, Inc.	Completed	18 Years	N/A	Both	20	Phase 2	United States